Commercial Biotech Leader | Board Member | Marketing | Sales | Rare Diseases | Vaccines | Launch
The recent article in JTH underscores the significant strides we've made in addressing immune-mediated thrombotic thrombocytopenic purpura (#ITTP). With compelling focus on efficacy, safety, and value. This transformative treatment approach not only reshapes the therapeutic strategy from day one but also promises better patient outcomes. #ITTP #aTTP #Sanofi
https://lnkd.in/gnGFF6sE In this JTH in clinic, five years of caplacizumab – lessons learned and remaining controversies in immune-mediated thrombotic thrombocytopenic purpura Linus Alexander Völker | Paul Thomas Brinkkoetter | Spero Cataland | Camila Masias MD